myPACE+ Algorithm for Hypertrophic Cardiomyopathy

(PACE-nHCM Trial)

This trial tests a new treatment approach for individuals with hypertrophic cardiomyopathy, specifically those whose hearts pump normally but experience heart failure symptoms. The study compares personalized accelerated pacing using the myPACE+ algorithm, a specialized pacing strategy, to usual care to determine if it improves symptoms, heart function, and overall quality of life. Participants will either have their heart's pacing adjusted based on the algorithm or continue with standard pacing. This trial suits individuals with non-obstructive hypertrophic cardiomyopathy, normal heart pumping action, and dual-chamber defibrillators already in place. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance treatment options for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that personalized accelerated pacing, such as the myPACE+ algorithm, is generally safe. Studies have found that this method can enhance heart health and exercise ability without major safety concerns. No specific reports of serious side effects have been linked to myPACE+, indicating that patients tolerate the treatment well. However, as with any new treatment, individual experiences may vary, so discussing potential risks with a doctor is important.¹²³⁴⁵

Researchers are excited about the myPACE+ algorithm for hypertrophic cardiomyopathy because it offers a personalized approach to pacing heart rates. Unlike the standard treatment, which typically maintains a fixed heart rate setting of 60 beats per minute, the myPACE+ algorithm adjusts the pacing based on each individual's resting heart rate. This tailored method could potentially improve heart function and quality of life for patients by aligning more closely with their unique physiological needs. By focusing on personalized care, myPACE+ might provide a more effective management strategy for those with hypertrophic cardiomyopathy.

Research has shown that the myPACE+ algorithm can assist people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens excessively. In this trial, participants in the myPACE+ arm will receive a personalized lower rate setting based on the myPACE+ resting heart rate algorithm. The myPACE trial found that using this algorithm for personalized pacing significantly improved quality of life. Specifically, participants reported feeling better and experiencing fewer heart failure symptoms. Although specific data from the study is not provided here, these early results suggest that the myPACE+ algorithm could be a promising tool for managing symptoms in HCM patients.³⁴⁶⁷⁸